The percentage of high-grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death.


Journal

Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 10 12 2018
revised: 23 04 2019
accepted: 24 04 2019
pubmed: 30 4 2019
medline: 29 2 2020
entrez: 30 4 2019
Statut: ppublish

Résumé

It has been recommended that the percentage of high-grade (HG) Gleason patterns 4 and 5 should be quantified in prostate cancer. However, this has not been assessed in a cohort using prostate cancer death as an outcome, and there is debate as to whether the biopsy with the 'worst' percentage of HG disease or an 'overall' percentage of HG disease should be reported. Such data may assist in active surveillance decisions. Men with clinically localised prostate cancer diagnosed by needle biopsy from 1990 to 2003 were included. The endpoint was prostate cancer death. Clinical variables included Gleason score (GS), prostate-specific antigen level, age, clinical stage, and disease extent. Deaths were divided into those from prostate cancer and those from other causes, according to World Health Organization criteria. Nine hundred and eighty-eight biopsy cases were centrally reviewed according to criteria agreed at the Chicago International Society of Urological Pathology conference in 2014. Cores were given individual GSs and Grade Groups (GGs), and a percentage of each grade was given for each core. Both the worst percentage of HG disease seen in a biopsy series and overall percentage of HG disease were calculated. The overall percentage of HG disease was highly significant, with a hazard ratio of 4.45 for the interquartile range (95% confidence interval 3.30-6.01, P < 2.2 × 10 These data validate the use of percentage of HG disease to predict prostate cancer death. As both worst and overall percentage of HG disease are powerful predictors of outcome, either could be chosen to provide prognostic information.

Identifiants

pubmed: 31032963
doi: 10.1111/his.13888
pmc: PMC6790619
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

589-597

Subventions

Organisme : ORCHID
Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : US National Cancer Institute
ID : P50CA09629
Organisme : Myriad Genetics
Organisme : David H. Koch Fund

Informations de copyright

© 2019 The Authors. Histopathology Published by John Wiley & Sons Ltd.

Références

BMC Urol. 2011 Oct 06;11:21
pubmed: 21978318
Eur Urol. 2016 Apr;69(4):592-598
pubmed: 26542947
J Urol. 2010 Feb;183(2):433-40
pubmed: 20006878
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
JAMA. 1999 Apr 21;281(15):1395-400
pubmed: 10217055
Mod Pathol. 2016 Jun;29(6):630-6
pubmed: 26939875
Am J Surg Pathol. 2016 Nov;40(11):1439-1456
pubmed: 27635949
Cancer. 1990 Sep 15;66(6):1225-33
pubmed: 2400973
J Clin Oncol. 2016 Jun 20;34(18):2182-90
pubmed: 26884580
Mod Pathol. 2017 Aug;30(8):1126-1132
pubmed: 28530220
Arch Pathol Lab Med. 2016 Oct;140(10):1140-52
pubmed: 26756649
Histopathology. 2019 Oct;75(4):589-597
pubmed: 31032963
J Urol. 2002 Aug;168(2):509-13
pubmed: 12131299
Eur Urol. 2018 May;73(5):674-683
pubmed: 28117112
Cancer Chemother Rep. 1966 Mar;50(3):125-8
pubmed: 5948714
Histopathology. 2018 Jul;73(1):5-7
pubmed: 29890013
Histopathology. 2015 Feb;66(3):438-46
pubmed: 25231130
J Clin Oncol. 2005 May 1;23(13):2911-7
pubmed: 15860849
J Clin Pathol. 2018 Oct;71(10):874-878
pubmed: 29720406
Am J Surg Pathol. 2016 Oct;40(10):1400-6
pubmed: 27379821
Histopathology. 2016 Sep;69(3):441-9
pubmed: 27028587
Can Urol Assoc J. 2015 May-Jun;9(5-6):171-8
pubmed: 26225165
J Urol. 2016 Aug;196(2):405-11
pubmed: 26920466
Histopathology. 2013 Jan;62(2):247-56
pubmed: 23240715
Hum Pathol. 2009 Apr;40(4):558-64
pubmed: 19144380
Histopathology. 2014 Feb;64(3):405-11
pubmed: 24102975
Eur Urol. 2016 Apr;69(4):599-600
pubmed: 26607687
Cancer. 2007 Nov 1;110(9):1967-72
pubmed: 17823907
Br J Cancer. 2016 May 10;114(10):1078-83
pubmed: 27100731

Auteurs

Daniel M Berney (DM)

Department of Molecular Oncology, Barts Cancer Institute, London, UK.

Luis Beltran (L)

Department of Molecular Oncology, Barts Cancer Institute, London, UK.

Holly Sandu (H)

UK Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.

Geraldine Soosay (G)

Department of Pathology, Queen's Hospital, Romford, London, UK.

Henrik Møller (H)

Department of Molecular Oncology, Barts Cancer Institute, London, UK.
School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.

Peter Scardino (P)

Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Jacqueline Murphy (J)

UK Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.

Amar Ahmad (A)

UK Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.

Jack Cuzick (J)

UK Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH